The gene encoding the transcription factor RFX4 represents an excellent neurobiological and positional candidate gene for Bipolar disorder due to the potential involvement of RFX4 proteins in the regulation of circadian rhythms and the proximity of the locus to numerous linkage signals on chromosome 12q23. In this study we have sought to identify common variants within the gene, which might confer risk to the disease in our large UK Caucasian sample of Bipolar patients (676 DSMIV Bipolar I probands, 690 controls). RFX4 was screened for sequence variants and the LD block structure across the genomic region determined using 22 biallelic polymorphisms (minor allele frequency Z0.1). Through analysis of 10 haplotypetagging markers and using a two-stage approach (subset I: 347 cases, 374 controls; subset II: 329 cases, 316 controls), we identified a haplotype at rs10778502 and ss24735177, which showed nominally significant disease association in our full sample (haplotype-specific P ¼ 0.002, global P ¼ 0.017; subset I: haplotype-specific P ¼ 0.0002, global P ¼ 0.0008; subset II: haplotype-specific P ¼ 0.572, global P ¼ 0.109). Evidence for potential disease association with mutations across the RFX4 region came also from the analysis of the nearby microsatellite D12S2072 (empirical P ¼ 0.009 in our full sample). Investigation of RFX4 brain cDNA tagged by rs10778502 provided evidence for significant allelic differences in expression (Po0.001), where some of the variance was accounted for by the genotype at ss24735177. Our findings thus indicate the potential functional relevance of the associated haplotype and now require replication in independent samples. Molecular Psychiatry (2005) 10, 920-927.
Bipolar affective disorder (BPD), also known as manic-depressive illness, is a common psychiatric disorder with a lifetime prevalence of 1%. 1 Genetic factors have been implicated in the aetiology of BPD by family, twin and adoption studies. [1] [2] [3] [4] [5] Independent linkage studies [6] [7] [8] [9] [10] [11] [12] have recently identified chromosome 12q23-24 as a genomic region that is likely to harbour at least one susceptibility locus for BPD. Interestingly, this region of the genome has been also implicated by several linkage studies in unipolar depression (UPD), 13, 14 a psychiatric disorder which is genetically related to BPD. 15 We have reported two pedigrees in which severe affective disorder (BPD and UPD) cosegregates with Darier's disease (DD), an autosomal dominant skin disorder. 6, 9 The gene for DD maps to 12q24.11, and consequently in these families there is linkage between affective disorder and markers on chromosome 12q23-24.1 (lod scores of 2.1 6 and 3.6, 9 respectively). Further meiotic mapping has identified an approximately 25 cM-wide broad linkage region of interest 16 defined as the region shared by all individuals with severe mood disorder within both pedigrees. The work described in the current report is a linkage disequilibrium (LD) based investigation of the gene encoding the regulatory factor X4 (RFX4), a functional candidate for Bipolar disorder that resides within the delineated linkage region on chromosome 12q23.11.
RFX proteins constitute an evolutionarily highly conserved family of transcription factors, which regulate the expression of their target genes by cooperative binding of symmetrical 'X-box' consensus sequences. 17 DNA docking is achieved through a unique 'winged-helix' DNA binding domain consisting of 76 conserved amino acids. 17, 18 So far, there are five known members of the RFX protein family in humans: RFX1, RFX2, RFX3, RFX4 and RFX5. 18, 19 In structure, RFX4 proteins seem to be most closely related with RFX1, RFX2 and RFX3 19 although, unlike these proteins, RFX4 is unable to exert transcriptional activation. Instead, it has been assumed that RFX4 might function as a transcriptional regulator through selective interaction with other RFX members. 19 However, to date, the physiological function and target genes of RFX4 proteins are not fully known. 20 Originally, the human RFX4 transcript was isolated as a partial cDNA from human breast cancer biopsy samples, which encoded a short RFX-like DNA binding domain fused to the first three exons of the oestrogen receptor 1. 21 Recently, two testis-specific alternative RFX4 splice products 19 and one brainspecific RFX4 variant 22 have also been described. In mouse, the expression of the brain-specific RFX4 variant appears to be localised in the suprachiasmatic nucleus (SCN), 20 the circadian pacemaker in mammals required for the control of daily rhythms in locomotor activity, hormone production and body temperature. 23 The gene can further be induced by light exposure in a subjective night-specific manner, which is characteristic of many circadian genes in the SCN. 20 Clinical features of BPD, such as cyclicity, seasonality of recurrence, diurnal mood variation and early morning awakening, suggest a disruption of circadian rhythms. 24 To date, three types of circadian rhythm abnormality have been described in BPD; blunting or loss of amplitude, phase advance and the doubling in length of the sleep-wake cycle from 24 to 48 h. 24 Correspondingly, Lithium, the main mood stabilising drug used to treat BPD, has been shown to delay the advanced phase of sleep, melatonin and temperature rhythms in these patients 25 and to increase the circadian period of firing rate rhythms of cultured SCN neurons in a concentration dependent manner. 26 It is therefore conceivable that RFX4 proteins through their potential role in the regulation of circadian patterns might be involved in the pathophysiology of BPD.
Given the functional and positional candidacy of the RFX4 locus, we performed a detailed association study of the gene in conjunction with allele-specific expression analyses with the aim to identify common disease variants, which might increase susceptibility to BPD.
In the present study we describe mutation detection analysis of the RFX4 locus in a panel of unrelated Bipolar I (BPI) patients, the analysis of the LD structure of the gene with 22 common SNPs/InsDels and the investigation of 10 haplotype-tagging (ht) markers in up to 676 patients and 690 controls. We further report the detection of a potential diseaseassociated haplotype and the identification of a strong cis-acting variation likely to be associated with variants constituting the haplotype.
Patients and methods

Patients
Our case-control panel included 676 unrelated British Caucasian patients (254 males, 422 females; mean age 48 years, SD 13 years) meeting DSM IV 27 criteria for BPI disorder. On average, probands suffered from more than six previous episodes of depression (mean 6.6, SD 9.9) and six previous episodes of mania (mean 6.0, SD 6.9). Approximately 74% of them had experienced symptoms of psychosis and 35% of them mood incongruent psychotic symptoms. The onset of impairment commenced on average at 26 years (SD 10 years). All cases were recruited from psychiatric outpatients clinics in South Wales and the Midlands of England and were interviewed by a trained psychiatrist using either SADS-L (Schedule for Affective Disorder and Schizophrenia, Lifetime Version) 28 or SCAN (Schedules for Clinical Assessment in Neuropsychiatry). 29 A final consensus best estimate lifetime diagnoses according to DSM IV was made on the basis of all available clinical information by two experienced clinicians. Unrelated British Caucasian controls were either recruited from the Blood Transfusion Service in Wales and England (580 individuals) or were patients, who were attending a family medical practitioner in South Wales for nonpsychiatric reasons (GP controls, 110 individuals). Blood donors were not screened for the absence of psychiatric illness as this will have little impact on the power of a case-control study when the studied disease has a population prevalence of approximately 1% as reported for BPD. 30 Our total comparison group comprised 690 individuals, which were group-matched with the BPI patients for age and sex (256 males, 434 females, mean age 42, SD 13 years). To facilitate LD mapping we employed a twostage screening strategy and genotyped our full sample in two subsets: a screening subset (subset I: 347 cases, 374 controls) and a follow-up sample (subset II: 329 cases, 316 controls). First, we investigated selected ht markers (see below) in subset I. Given the presence of suggestive allelic, genotypic or haplotypic association, these markers were then followed up in subset II.
We obtained ethics committee approval for the study from the relevant research ethics committees and all individuals provided written informed consent for participation. Approximately 500 mg of each brain sample was selected for DNA extraction, which was performed according to standard phenol/chloroform-based laboratory procedures. From a similar amount of tissue (300-500 mg), total mRNA was isolated using the RNAwiz isolation reagent (Ambion, Huntingdon, UK). cDNA synthesis on DNase-treated total mRNA was carried out with the RETROscript kit (Ambion, Huntingdon, UK) following the manufacturer's protocol. RNA samples did not produce detectable levels of Potential Bipolar risk haplotype within the RFX4 gene B Glaser et al PCR product in the absence of a reverse transcriptasereaction step.
Brain samples
Mutation detection and sequencing
A transcript map of the RFX4 locus was created using the Golden Path Genome Browser Freeze July 03 (http://genome.ucsc.edu/). Putative promoter regions were identified with the predictive package NIX (http://www.hgmp.mrc.ac.uk/) and the Cister software (http://zlab.bu.edu/~mfrith/cister.shtml). Coding sequence, 5 0 /3 0 -UTR, promoter regions (B2000 bp upstream sequence) and at least 50 bp intronic sequence adjacent to each exon were screened for sequence variants in a panel of 15 unrelated Caucasian BPI individuals. Primers were designed using the Primer3 program (http://www. genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Variation detection analysis was carried out by denaturing high performance liquid chromatography (dHPLC) as described by Jacobsen et al. 31 All samples showing heteroduplex traces were subsequently sequenced with BigDyet Terminator Cycle Sequencing v.2.0 sequencing kit and resolved on an ABI3100 sequencer (PE Applied Biosystems, Warrington, Cheshire, UK).
LD/haplotype analysis
The LD measures D and r 2 were calculated with the Asthma GOLD program 32 and the LD structure of the region identified with the Haploview program (http:// www.broad.mit.edu/mpg/haploview/). Ht markers were chosen as predicted by the Haploview program (including haplotypes with frequencies Z2%) in conjunction with inter-marker r 2 -measures of r0.9. Haplotype frequencies for marker combinations in the case-control sample were computed with the UN-PHASED program (option COCAPhase) 33 based on likelihood ratio tests in a log-linear model. These haplotype frequencies also formed the basis for the calculation of diplotype probabilities in doubly heterozygous samples, as these individuals can, for two biallelic markers, adopt one of two possible diplotypes. The probability for a diplotype within a doubly heterozygous individual was defined as the frequency of the diplotype of interest (product of haplotype frequencies) divided by the sum of the frequencies for all possible diplotypes (product of haplotype frequencies for diplotype of interest þ product of haplotype frequencies for alternative diplotype).
Genotyping of markers
SNPs for LD mapping were either genotyped using the AcycloPrimet-FP SNP Detection Kit (Perkin-Elmer Life Sciences, Zaventern, Belgium) or by allelespecific PCR employing the Amplifluort SNPs HT Genotyping System FAM-SR (Serologicals, Norcross, GA, USA). The reactions were performed according to the manufacturer's protocol and analysed on an Analystt AD (LJL Biosystems, Sunnyvale, CA, USA). InsDels and the microsatellite were typed with 5 0 -fluorescently labelled PCR primers (FAM, TET or HEX dye). PCR products for several markers were combined and resolved on an ABI377 or ABI3100 sequencer. The data were analysed with Genescan v.3.0/Genescan v.3.7 and Genotyper v.2.5 software.
Allele-specific expression assay Common transcribed biallelic polymorphisms were chosen as copy-specific tags for mRNA variants to investigate potential differences in allele-specific expression. Based on single-exonic sequence, a PCR product was constructed around each selected variant thus providing similar analytical conditions for both genomic and cDNA PCR amplification. Using the designed PCR primers, a set of 60 genomic brain DNA samples corresponding to a set of brain cDNAs (see above) was subsequently screened for heterozygotes. Allele-specific expression analyses were performed for all identified heterozygous individuals using the highly sensitive SNaPshot primer extension technique (ABI PRISM s SNaPshot Multiplex Kit; PE Applied Biosystems, Warrington, Cheshire, UK) as outlined by Bray et al. 34 The samples were electrophoresed on an ABI3100 sequencer and the peak heights of the allele-specific extended reaction products measured with Genotyper v.2.5 software. A t-test for dependent samples was employed to compare allele-specific ratios between cDNA and genomic DNA. Genotype-specific expression differences among brain samples were assessed using a ttest for independent samples with unequal variances.
Statistical analysis
Allele-and genotype-wise biallelic marker frequencies between case and control individuals were compared using a standard w 2 -test, microsatellite marker frequencies were compared using a MonteCarlo-algorithm as implemented in CLUMP. 35 
Results
LD mapping of the RFX locus
The LD structure across the RFX4 locus (B210 kb), spanning all three known reference sequences (NM_032491, NM_002920, NM_213594) and the oestrogen receptor-like sequence M69296, was elucidated using 22 common SNPs/InsDels (minor allele frequency Z0.1) spaced at an approximate intermarker distance of 10 kb (see Figure 1a) . The polymorphisms were either identified by mutation screening or derived from public databases. The sequence of four new common mutations (ss24735173, ss24735174, ss24735175 and ss24735177) was submitted to the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/index.html). In order to guide the selection of ht markers in our investigated population of British Caucasian patients and controls, we examined the chosen 22 markers in a small set of individuals (N ¼ 94) included in our large outbred panel. This analysis revealed the presence of two distinct haplotype blocks across the RFX4 region (10 and 190 kb respectively; see Figure 1b) . Location of the block boundaries and lengths of the blocks were consistent with the data on the Hapmap server (www.hapmap.org).
Selection and genotyping of ht markers
Based on the predictions of the Haploview program in conjunction with intermarker r 2 -measures of r0.9, a set of 10 ht markers was chosen likely to capture the haplotype diversity in the investigated region. This set comprised the markers rs1991296, rs919092, ss24735173, ss24735174, rs1882543, rs10861647, rs5800715, rs7961392, rs10778502 and ss24735177 and was investigated in our large case-control sample according to our two-stage screening strategy. None of the studied ht markers showed evidence for allelic or genotypic disease association in any of the subsets investigated, nor when both subsets were combined. Complete genotyping information is detailed as Electronic supplement (Table I ). All marker genotypes were consistent with Hardy-Weinberg equilibrium.
Strongest evidence for disease association in subset I was found for a haplotype including the synonymous SNP rs10778502 and the intronic InsDel ss24735177, where we observed an excess of the 'CIns phase' in patients compared to controls (haplotype-specific P ¼ 0.0002; global P ¼ 0.0008; see Table  1 ). rs10778502 and ss24735177 were further investigated in subset II, but no replication of the signal could be observed (haplotype-specific P ¼ 0.572; global P ¼ 0.109; see Table 1 ). However, when the data from the two subsets were combined significant association of rs10778502-ss24735177 with BPD (haplotype-specific P ¼ 0.002, global P ¼ 0.017 see Table 1 ) remained.
Gender-specific analysis on our full data set was performed and revealed evidence for disease association in males (haplotype-specific P ¼ 0.003, global P ¼ 0.019) but not in females (haplotype-specific P ¼ 0.099, global P ¼ 0.387). However, the differences in the distribution of the 'C-Ins' haplotype phase at rs10778502-ss24735177 between the two sexes were not statistically significant (P ¼ 0.185).
Evidence for potential association between markers across the RFX locus and BPD was also suggested through the analysis of the microsatellite D12S2072, which resides within intron 17 of the gene (see Figure  1) . The alleles at the polymorphism were significantly associated with the disease in our full sample (empirical P ¼ 0.009; data not shown) and in strong LD with alleles at rs10778502 and ss24735177 (D 0 ¼ 0.83-0.99). However, haplotype analysis including alleles at all three markers did not provide increased evidence for disease association (P ¼ 0.04).
Allele-specific expression analyses of RFX4 mRNA sequences Given that the potentially associated polymorphisms have no obvious effect on protein structure, we investigated the hypothesis that they may be associated with variation in gene expression. We therefore studied potential differences in allele-specific RFX4 mRNA expression using cDNA carrying the polymorphism rs10778502.
rs10778502 (T/C allele-0.64/0.36) is transcribed within testis-specific NM_002920 and NM_032491 mRNA, brain-specific NM_213594 mRNA and two further mRNAs with exons shared by the first three reference sequences (ie AK074913 isolated from a teratocarcinoma NT2 cell line and testis-specific AL833921; Golden Path Freeze July 03). In order to monitor regulatory influences affecting differently spliced products in brain, we constructed two transcript-specific amplicons: a 65 bp PCR fragment shared by NM_002920, NM_032491, NM_213594, AK074913 and AL833921 mRNA, as well as a longer 145 bp fragment specific to the first four sequences (see Figure 2) .
Irrespective of the investigated amplicon, the analysis of RFX4 cDNA tagged by rs10778502 revealed strong evidence for allele-specific regulation of expression of the transcribed sequences. The expression study on 21 heterozygous individuals using the 145 bp fragment showed a consistent increase in average T/C cDNA ratio (corrected ratio ¼ 2.2470.18, 95% CI 2.16-2.31; Po0.001) compared to the corrected average genomic ratio (see Figure 3a) . Each of the analysed samples demonstrated a relative rise in allelic cDNA ratio ranging between 108 and 180%. This augmented T/C cDNA ratio (corrected ratio ¼ 1.8270.14, 95% CI 1.76-1.88) could also be observed to a lesser extent when the analysis was performed with the 65 bp amplicon, which additionally included AL833921 (Po0.001; see Figure 3b ). Correlation of the allelic alterations measured for each analysed individual under the two experimental settings confirmed the equivalency of the data sets (Pearson correlation coefficient ¼ 0.75).
Given that the strongest evidence for an association with BPD was yielded by a two-marker haplotype including rs10778502 and the intronic InsDel ss24735177, the expression results for rs10778502 (145 bp fragment) were additionally stratified according to the putative disease-associated haplotype phase present in genomic DNA to investigate whether this accounted for any of the cis-acting variation.
For individuals doubly heterozygous at the two markers, the probability (based on COCAPhasederived haplotype frequencies) is 99% that the diplotype phase for rs10778502 and ss24735177 is C-Del/T-Ins. In the remaining informative brain samples, the diplotype is C-Ins/T-Ins. Using the common T-Ins haplotype as a reference point, the C allele showed a trend (P ¼ 0.079) for lower expression when it was in phase with the Ins variant than when it was in phase with the Del. This is reflected by a higher T/C ratio for the C-Ins phase (corrected average T/C cDNA ¼ 2.3570.23, 95% CI 2.51-2.20) compared to the C-Del phase (T/C cDNA ¼ 2.1970.10, 95% CI 2.26-2.12). N, number of haplotypes. a Estimated haplotype frequencies by COCAPhase; P (C-Ins), C-Ins haplotype-specific P-value.
Potential Bipolar risk haplotype within the RFX4 gene B Glaser et al
Discussion
We have undertaken a detailed candidate gene study of the RFX4 locus on chromosome 12q23 in combination with allele-specific expression analyses of RFX4 transcripts with the aim to identify common RFX4 variants, which might confer risk to BPD in the general population. Through LD mapping of the 210 kb genomic region harbouring the RFX4 gene and subsequent selection and analysis of 10 ht markers, we were able to identify a haplotype at the synonymous SNP rs10778502 and a novel InsDel ss24735177, which was significantly associated with BPD in our combined data set. Across this haplotype we observed an excess of the 'C-Ins' phase in patients compared to controls. The potential haplotypic disease association at the two markers was furthermore supported by the analysis of the microsatellite D12S2072. The results that we have presented are nominal significance levels uncorrected for multiple testing. If we allow for examining nine different two-locus sliding-window haplotypes using a Bonferroni correction, the global significance found in our screening set remains significant (corrected global P ¼ 0.0072) However, we also examined several other candidate genes within the 25 cM wide linkage region of interest on 12q23-24.1 16, 31, [36] [37] [38] and observed one positive LD signal across the Cux2/FLJ32356 region. 37 Clearly, our results have to be interpreted within this context and, as both investigated subsets had approximately the same power (power subset I ¼ 0.89 and power subset II ¼ 0.85; http://calculators.stat.ucla.edu/powercalc/binomial/case-control/), replication of our data in independent samples, preferably from groups with linkage signals in this region, is required.
Investigation of RFX4 within members of the two Darier families segregating major affective disorder showed that the risk haplotype was not segregating with disease (data not shown). Moreover, dHPLC screening of the exons, splice-sites and promoter did not reveal other variants that could explain the pattern of the illness in these pedigrees (data not shown). However, it remains possible that we have missed highly penetrant variants elsewhere in RFX4 that confer susceptibility in these highly loaded families.
If the detected haplotypic association represents a true positive finding, the two variants rs10778502 and ss24735177 might either have pathogenic potential themselves or may act as proxies as many polymorphisms within RFX4 are highly correlated with them (see Electronic supplement Table II ).
In the absence of nonsynonymous changes that could explain our findings, we investigated the possibility that the associated haplotype might index risk for Bipolar disorder by tagging an allele that alters RFX4 expression. Our analyses provided evidence for the existence of such a cis-acting polymorphism with highly significant (Po0.001) allelic expression differences being obtained in two complementary assays. In each, the C allele at rs10778502 was expressed at a much lower level than the T allele. Stratification of our data revealed that mRNA originating from chromosomes carrying the C-Ins risk haplotype was expressed at a lower level than all other haplotypes. It is, therefore, possible that altered expression of RFX4 transcripts resulting from the action of cis-acting sites associated with both rs10778502 and ss24735177 is a mechanism by which this haplotype could be associated with susceptibility to BPD. However, the difference between the C-ins and the C-Del haplotype was small compared with the effect of the C allele alone, and only showed a trend towards statistical significance (P ¼ 0.079) although this might be due to the small number of doubly heterozygous samples Figure 3 Allele-specific expression analyses using transcribed RFX4 variants. (a) Variation in allelic RFX4 mRNA expression as assayed through rs10778502 using a 145 bp fragment (shown as allelic T/C ratio); Allelic T/C cDNA and genomic ratios are normalised against the average genomic ratio; The selected PCR fragment is transcribed within the sequences NM_002920, NM_032491, NM_213594 and AK074913. (b) Variation in allelic RFX4 mRNA expression as assayed through rs10778502 using a 65 bp fragment (shown as allelic T/C ratio); allelic T/C cDNA and genomic ratios are normalised against the average genomic ratio; the selected PCR fragment is transcribed within the sequences NM_002920, NM_032491, NM_213594, AK074913 and AL833921.
investigated. We would expect that if risk of BPD were related to low expression of RFX4, the C allele on its own would show evidence for association. Individual genotyping analysis of rs10778502 in the combined data set revealed however that the allele distribution at the polymorphisms only approached nominally significant disease association in the combined data set (nominal P ¼ 0.06; Electronic supplement Table II) .
Variants of the putative susceptibility haplotype could either be in LD with regulatory polymorphisms affecting RFX4 expression or could exert a direct effect as both markers reside in evolutionary highly conserved regions as indicted by VISTA analysis (http://www-gsd.lbl.gov/vista/index.shtml). In silico inspection of the exonic region around rs10778502 using the ESEfinder program (http://exon.cshl.org/ ESE/index.html) also revealed the absence of a highly conserved exonic splicing enhancer for the serine/ arginine-rich protein SRp40 in mRNA carrying the C allele compared to mRNA carrying the U(T) allele (data not shown). This would support the hypothesis that precursor mRNA carrying the C-allele might be less efficiently spliced, due to, for example, a diminished binding of SRp40, and result more often in the generation of aberrant RNA than the splicing of precursor mRNA carrying the U(T) allele at rs10778502. Thorough experimental analysis, however, is required in order to elucidate this hypothesis further.
In conclusion, the current study demonstrates the association of BPD with a haplotype at RFX4 derived from marker rs10778502 and ss24735177. Investigation of RFX4 brain cDNA tagged by rs10778502 provided evidence for significant differences in allelic expression, which might be modulated through variation at ss24735177. As with all studies of complex disease, it is important that our findings are replicated in large independent samples.
